Pharmacoepidemiology: Recent findings and challenges for child and adolescent psychopharmacology

Journal of Clinical Psychiatry

Volumn 68, Issue 6, 2007, Pages 966-967

  Zito, Julie Magno ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; GABAPENTIN; MOOD STABILIZER; VALPROATE SEMISODIUM;

AGGRESSION; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DRUG UTILIZATION; HUMAN; HYPOTHESIS; IMPULSE CONTROL DISORDER; INFORMATION PROCESSING; MEDICAL RESEARCH; OVARY POLYCYSTIC DISEASE; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; SEIZURE; SHORT SURVEY; STATISTICAL ANALYSIS;

EID: 34347329023     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/jcp.v68n0622     Document Type: Short Survey

References (27)

1. Strom BL. Pharmacoepidemiology. 4th ed. West Sussex: John Wiley and Sons, Ltd; 2005
2. Zito JM, Safer DJ, Craig TJ. Pharmacoepidemiology of psychiatric disorders. In: Hartzema AG, Porta MS, Tilson HH, eds. An Introduction to Pharmacoepidemiology. Cincinnati, Ohio: Harvey A. Whitney Books. In press
3. Baldessarini RJ, Leahy L, Arcona S, et al. Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders. Psychiatr Serv 2007;58:85-91
4. Zito JM, Safer DJ, dosReis S, et al. Psychotropic practice patterns for youth: a 10-year perspective. Arch Pediatr Adolesc Med 2003;157:17-25
5. Hunkeler EM, Fireman B, Lee J, et al. Trends in use of antidepressants, lithium, and anticonvulsants in Kaiser Permanente-insured youth, 1994-2003. J Child Adolesc Psychopharmacol 2005;15:26-37
6. Hauser WA, Annegers JF, Kurland LT. Prevalence of epilepsy in Rochester, Minnesota: 1940-1980. Epilepsia 1991;32: 429-445
7. Cowan LD, Bodensteiner JB, Leviton A, et al. Prevalence of the epilepsies in children and adolescents. Epilepsia 1989;30:94-106
8. Zito JM, Safer DJ, Gardner JF, et al. Anti-convulsant treatment for psychiatric and seizure indication among youths. Psychiatr Serv 2006;57:681-685
9. Wagner KD, Kowatch R, Emslie GJ, et al. A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Am J Psychiatry 2006; 163:1179-1186
10. DelBello MP, Findling RL, Kushner S. et al. A pilot controlled trial of topiramate for mania in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2005;44:539-547
11. Wagner KD, Weller EB, Carlson GA, et al. An open-label trial of divalproex in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2002; 41:1224-1230
12. Joffe H, Cohen LS, Suppes T, et al. Longitudinal follow-up of reproductive and metabolic features of valproate-associated polycystic ovarian syndrome features: a preliminary report. Biol Psychiatry 2006; 60:1378-1381
13. Wyszynski DF, Nambisan M, Surve T, et al, Antiepileptic Drug Pregnancy Registry. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005;64:961-965
14. Bryant AE, Dreifuss FE. Valproic acid hepatic fatalities, III. U.S. experience since 1986. Neurology 1996;46:465-469
15. Dreifuss FE, Santilli N, Langer DH, et al. Valproic acid hepatic fatalities: a retrospective review. Neurology 1987;37:379-385
16. Scheffner D, Konig S, Rauterberg-Ruland I, et al. Fatal liver failure in 16 children with valproate therapy. Epilepsia 1988;29: 530-542
17. Roberts R, Rodriguez W, Murphy D, et al. Pediatric drug labeling: improving the safety and efficacy of pediatric therapies. JAMA 2003;290:905-911
18. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med 2006;166: 1021-1026
19. Duffy FF, Narrow WE, Rae DS, et al. Concomitant pharmacotherapy among youths treated in routine psychiatric practice. J Child Adolesc Psychopharmacol 2005;15:12-25
20. Safer DJ, Zito JM, DosReis S. Concomitant psychotropic medication for youths. Am J Psychiatry 2003;160:438-449
21. Turner S, Nunn AJ, Fielding K, et al. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr 1999;88: 965-968
22. Martin A, Van Hoof T, Stubbe D, et al. Multiple psychotropic pharmacotherapy among child and adolescent enrollees in Connecticut Medicaid managed care. Psychiatr Serv 2003;54:72-77
23. dosReis S, Zito JM, Safer DJ, et al. Multiple psychotropic medication use for youths: a two-state comparison. J Child Adolesc Psychopharmacol 2005;15:68-77
24. Texas Health and Human Services Commission. Use of psychoactive medication in Texas foster children, state fiscal year 2005. Available at: http:/www.hhs.state.tx.us/news/release/Analysis_062306.pdf. Accessibility verified April 17, 2006
25. Pincus HA, Tew JD, First MB. Psychiatric comorbidity: is more less? World Psychiatry 2004;3:18-23
26. Best Pharmaceuticals for Children Act. Pub. L. No. 107-109, Pub. L. No. 107-109. 115 Stat. 1408 (2002) (codified as amended at 42 U.S.C.A. § 284m (West 2003), 21 U.S.C.A. § 355b (West Supp. 2003). 21 U.S.C.A. § 393a (West Supp. 2003); 2002
27. American Public Health Association Policy Statement. Regulating drugs for effectiveness and safety: a public health perspective. Policy Number 200613; 2006. Available at: www.apha.org/advocacy/policy/policysearch/default.htm. Accessibility verified April 17, 2007